CHAMBER HILL STRATEGIES

Lobbying for OS THERAPIES · biotechnology company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · New York · House · Senate · posted Jan 20, 2026

Lobbying activity 2

Pharmacy

cancer immunotherapy and antibody treatment; osteosarcoma

Health Issues

cancer immunotherapy and antibody treatment; osteosarcoma

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.